Checking blood flow control in the brain during stroke clearing procedures to predict recovery
Studies whether brain blood flow control predicts poor recovery after thrombectomy in stroke patients.
Plain-language title generated from the registry record
Registry title: Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation
Key facts
- Where
- Beijing, Dalian, Harbin, and Weifang, ChinaSee the 4 sites
Where in China
- Beijing Shijitan Hospital, Capital Medical UniversityBeijing, ChinaTaking people
- Dalian Municipal Central HospitalDalian, ChinaNot yet recruiting
- The First Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaTaking people
- Weifang People's Hospital Affiliated to Weifang Medical UniversityWeifang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Shijitan Hospital, Capital Medical University
- Trial code
- NCT07556068
- Record updated
- 6 May 2026
- Original description
This multicenter, prospective, observational diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment. The study aims to determine whether impaired cerebral autoregulation during thrombectomy can serve as an ultra-early biomarker for predicting futile recanalization in patients with acute ischemic stroke.Read full original descriptionShow less
Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation Monitoring: a Multicenter, Prospective, Observational Study
This multicenter, prospective, observational diagnostic accuracy study enrolls patients undergoing thrombectomy with intraoperative cerebral autoregulation monitoring and follows them up at predefined time points up to 90 days post-enrollment. The study aims to determine whether impaired cerebral autoregulation during thrombectomy can serve as an ultra-early biomarker for predicting futile recanalization in patients with acute ischemic stroke.
Inclusion: Age ≥ 18; Clinical signs consistent with acute ischemic stroke with large vessel occlusion in the anterior circulation (intracranial segment of the internal carotid artery, middle cerebral artery M1 segment) demonstrated with CTA/MRA/DSA; NIHSS score ≥ 6 obtained prior to endovascular treatment; Modified Rankin Scale ≤ 1 prior to qualifying stroke; Acute ischemic stroke, undergone endovascular treatment within 24 hours of onset (time of stroke is the last known normal for wake-up stroke or with unknown onset time).with reaching the goal of mTICI grade 2b-3; For patients with symptom onset within 6 hours: ASPECTS ≥ 3; for patients with symptom onset between 6 and 24 hours: age ≤ 80 years and ASPECTS ≥ 3; Patient/Legally Authorized Representative has signed the Informed Consent Form.
Exclusion: Untreated moderate or severe coronary artery stenosis, or previous coronary artery bypass surgery; Current participation in another investigational drug or device study; Evidence of intracranial hemorrhage or hemorrhagic transformation before thrombectomy; Known allergies or intolerances to antiplatelet agents, anticoagulation drugs, iodinated contrast and/or anesthetics; Severe infection (e.g. sepsis) or multiple organ failure; Refractory hypertension that is difficult to control by medication (Defined as persistent systolic blood pressure>185 mmHg or diastolic blood pressure>110 mmHg); Malignant brain tumor or CNS infection; Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations (e.g., dementia or mental illness); local skin damage or other conditions that cannot cooperate with electrode sticking; severe agitation or other conditions affecting data collection; Known hereditary or acquired hemorrhagic diathesis or coagulation factor deficiency; oral anticoagulant therapy with INR > 3; or use of a factor Xa inhibitor within the preceding 48 hours with an abnormal aPTT; Baseline platelet count < 50 × 10\^9/L; Blood glucose concentration<50 mg/dL (2.7 mmol/L) or >400 mg/dL (22.2 mmol/L); Severe cardiomyopathy with heart failure (LVEF ≤ 30% or NYHA class IV), acute myocardial infarction, or unstable angina; Current hemodialysis or peritoneal dialysis; known severe renal insufficiency with estimated glomerular filtration rate < 30 mL/min or serum creatinine > 220 μmol/L (2.5 mg/dL); Baseline CT/MRI confirms the presence of multiple vascular territory acute strokes; Baseline CT/MRI confirms the presence of arterial dissection; Known intracranial aneurysm, and cerebral arteriovenous malformation; Female who is pregnant or lactating at time of admission; Anticipated life expectancy < 6 months.